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OBJECTIVE — To validate the ability of the Archimedes model to accurately predict the risk
of developing diabetes in individuals.
RESEARCH DESIGN AND METHODS — Subjects were randomly selected from the
San Antonio Heart Study population. The area under the receiver operating characteristic
(aROC) curve derived from the Archimedes model was calculated and also compared with the
aROCs from two published multiple logistic regression models designed to estimate diabetes
risk.
RESULTS — The aROC for the Archimedes model was 0.818 (95% CI 0.739–0.899) com-
pared with aROCs of 0.869 (0.801–0.936) and 0.870 (0.802–0.937) for the two logistic regres-
sionmodels,respectively.Riskestimatesfromthelogisticmodelswerehighlycorrelatedwiththe
estimates derived from the Archimedes model.
CONCLUSIONS — The Archimedes model predicts individual diabetes risk with a high
level of sensitivity and speciﬁcity, comparable with that of models designed speciﬁcally for that
purpose. Unlike the latter models, Archimedes also predicts the risk of numerous other health
outcomes.
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T
he Archimedes model is a large-
scale simulation model of human
physiology and health care sys-
tems (1). It has been extensively vali-
dated by its ability to quite closely
replicate a wide variety of aggregate
healthoutcomesinpopulations(1).The
ability of Archimedes to make accurate
predictions for individuals, however,
has thus far not been validated. Using
data from the San Antonio Heart Study
(SAHS), we attempted such a valida-
tion. We also compared the area under
the receiver operating characteris-
tic curves (aROCs) derived from
Archimedes with those derived from
two other diabetes predicting models,
namely, the SAHS predicting model (2)
and the Atherosclerosis Risk in Com-
munities (ARIC) predicting model (3).
RESEARCH DESIGN AND
METHODS— The SAHS is a prospec-
tive cohort study consisting of 3,682 in-
dividuals (62% Mexican American and
38% non-Hispanic white) followed for
7–8 years (4). The SAHS predicting
model is a multiple logistic regression
model with incident diabetes as the de-
pendent variable and a panel of baseline
characteristicsthatareordinarilyavailable
in a routine clinical setting as independent
variables (2). The ARIC predicting model is
a similarly constructed logistic regression
model (3).
The Archimedes model is built from
underlying anatomy and physiology and
uses scores of ordinary and differential
equations to represent metabolic pathways,
occurrence and progression of diseases,
signs and symptoms, treatments, and out-
comes. A practical, free, readily available
tool derived from the Archimedes model is
the American Diabetes Association’s Diabe-
tes PHD (Personal Health Decisions; avail-
able at http://diabetes.org/diabetesPHD).
Diabetes PHD can simultaneously predict
the risk of diabetes and numerous other
outcomes, including the effects of a wide
variety of treatments in many different
populations (e.g., those with diabetes). It
was used here to provide external valida-
tion of its prediction of the incidence of
diabetes.
Among the 3,228 individuals in the
SAHS who were nondiabetic at baseline,
295 developed diabetes over the 7–8
years of follow-up. All the required ele-
ments for the Archimedes risk estimation
were available in the subjects selected for
thepresentanalyses.Thepresentanalyses
were restricted to the recent cohort 2 of
SAHS, which included 1,734 nondiabetic
individuals,195ofwhomwerediabeticat
follow-up. Within the SAHS database, we
selected 100 individuals at random, 50 of
whom were diabetic at follow-up and 50
who remained free of diabetes at follow-
up. This sample size would provide 80%
power to detect an aROC signiﬁcantly
(P  0.05) greater than 0.70 (the low end
of acceptable discrimination [5]) if the
true aROC was 0.80 and 90% power if
the true aROC was 0.83 (benchmark val-
ues near that of other established models)
(2,3).
The risk of developing diabetes for
each individual was determined accord-
ing to the years of follow-up for that indi-
vidual (rounded to the nearest year),
which ranged from 6–9 with a mean of
7.5. Data from each individual were en-
tered into Diabetes PHD and the results
obtained from the graphical output dis-
played on the computer screen. A second
person conﬁrmed the accuracy of the in-
put and, in a random sample of 20 forms,
also conﬁrmed the output from Diabetes
PHD.
We also estimated the risk of diabetes
for the same 100 individuals using both
the SAHS diabetes predicting model and
the ARIC predicting model. The aROC’s
and CIs for all three models were com-
puted and compared (6). Finally, we
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ﬁcients between the risk estimates ob-
tained from each pair of predicting
models.
RESULTS— The aROC for Diabetes
PHD was 0.818 (95% CI 0.739–0.899)
and was not statistically different than the
aROCoftheSAHSmodel(0.869[95%CI
0.801- 0.936]) or the ARIC model (0.870
[0.802–0.937]) (Fig. 1). The risk esti-
mates from the SAHS model and ARIC
modelwerehighlycorrelated(r0.962),
and both correlated well with Diabetes
PHD (r  0.834 and 0.842, respectively).
CONCLUSIONS — WithanaROCof
0.818, it is evident that the accuracy of
Diabetes PHD (i.e., Archimedes) to pre-
dict an individual’s risk of diabetes is
excellent—almost as high as models spe-
ciﬁcally designed and used only for that
purpose. The SAHS model may have had
an unfair advantage over Archimedes be-
cause it was designed and optimized us-
ing the SAHS database and could be
overﬁtted to the subset of SAHS cases se-
lected for this analysis. It was for that rea-
son that we used the ARIC predicting
model: the latter was developed in an en-
tirely independent dataset and performed
as well as the SAHS model.
Both the SAHS and ARIC models
were built from person-speciﬁc data and
optimized speciﬁcally for predicting inci-
dent diabetes. In contrast, Archimedes
was designed to be used for a very wide
rangeofpurposes,calculatesmanydiffer-
ent outcomes, was not built from person-
speciﬁc data, and was not calibrated to
determinetheincidenceofdiabetes.Also,
several of the variables Archimedes uses
that may have enhanced its predictive ca-
pabilitywerenotincludedinthisanalysis.
This report extends the validation of
Archimedes and demonstrates its excel-
lent ability to discriminate between indi-
viduals who will or will not develop
diabetes. Its utility is comparable with
modelsdevelopedsolelyforthatpurpose.
Because Diabetes PHD, derived from
Archimedes, is freely available on the in-
ternet and calculates many additional
outcomes, it is a powerful tool that can be
reliably used for comprehensive risk as-
sessment and decision making. Diabetes
PHD is now widely accessed (80,000
users per year) for use in comprehensive
risk assessment of cardiometabolic dis-
ease over a 30-year period and that helps
diabetic patients better appreciate the
likely beneﬁts of risk factor reduction. Al-
though the tool currently uses complex
distributive computing, which limits its
speed and capacity, a much more rapid
version will soon become available with
unlimited capacity. This will allow for
widespread promotion.
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